Open Access

Expression of CREPT is associated with poor prognosis of patients with renal cell carcinoma

  • Authors:
    • Huaqi Yin
    • Qingfei Cao
    • Haiyue Zhao
    • Shenheng Wang
    • Weinan Chen
    • Xiaowei Zhang
    • Zhijie Chang
    • Tao Xu
    • Xiongjun Ye
  • View Affiliations

  • Published online on: September 9, 2019     https://doi.org/10.3892/ol.2019.10831
  • Pages: 4789-4797
  • Copyright: © Yin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cell‑cycle‑associated and expression‑elevated protein in tumor (CREPT) functions as a cell cycle modulator that enhances the transcription of cyclin D1 by interacting with RNA polymerase II. CREPT has been identified to be overexpressed in various human cancer types; however, the expression and significance of CREPT in renal cell carcinoma (RCC) has remained largely elusive. In the present study, increased expression of CREPT was identified in 46.7% RCC tissues compared with adjacent normal tissue (31.1%; P=0.032) using immunohistochemistry. Furthermore, overexpression of CREPT was significantly associated with the Tumor‑Node‑Metastasis stage (χ2=11.967, P=0.001) and Fuhrman grade (χ2=15.453, P<0.001). In addition, increased expression of CREPT was associated with poor overall survival (P=0.021) and disease‑free survival (P=0.015) of patients according to Kaplan‑Meier analysis. Cellular function assays demonstrated that knockdown of CREPT in the 786‑O and 769P RCC cell lines suppressed their proliferative, colony formation, migratory and invasive capacity and led to cell cycle arrest in the G1 phase. In addition, the western blotting analysis demonstrated that CREPT may control the cell cycle through downregulation of cyclin D1 and c‑myc. Collectively, the overexpression of CREPT was indicated to be a negative prognostic factor for RCC, and CREPT may serve as a novel therapeutic target for the treatment of RCC.
View Figures
View References

Related Articles

Journal Cover

November-2019
Volume 18 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yin H, Cao Q, Zhao H, Wang S, Chen W, Zhang X, Chang Z, Xu T and Ye X: Expression of CREPT is associated with poor prognosis of patients with renal cell carcinoma. Oncol Lett 18: 4789-4797, 2019
APA
Yin, H., Cao, Q., Zhao, H., Wang, S., Chen, W., Zhang, X. ... Ye, X. (2019). Expression of CREPT is associated with poor prognosis of patients with renal cell carcinoma. Oncology Letters, 18, 4789-4797. https://doi.org/10.3892/ol.2019.10831
MLA
Yin, H., Cao, Q., Zhao, H., Wang, S., Chen, W., Zhang, X., Chang, Z., Xu, T., Ye, X."Expression of CREPT is associated with poor prognosis of patients with renal cell carcinoma". Oncology Letters 18.5 (2019): 4789-4797.
Chicago
Yin, H., Cao, Q., Zhao, H., Wang, S., Chen, W., Zhang, X., Chang, Z., Xu, T., Ye, X."Expression of CREPT is associated with poor prognosis of patients with renal cell carcinoma". Oncology Letters 18, no. 5 (2019): 4789-4797. https://doi.org/10.3892/ol.2019.10831